ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
ASTRAZENECA PLC ADRhedged
53.28
0.0000
成交量：
- -
成交額：
- -
市值：
159.83萬
市盈率：
- -
高：
53.28
開：
53.28
低：
53.28
收：
53.28
52周最高：
56.90
52周最低：
44.36
股本：
3.00萬
流通股本：
1.00萬
量比：
- -
換手率：
- -
股息：
0.58
股息率：
1.08%
淨資產收益率：
--
總資產收益率：
--
市淨率：
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
阿斯利康長效C5補體抑制劑偉立瑞獲批上市
南方财经网
·
08/20
偉立瑞®在華獲批用於治療成人和1月齡及以上兒童陣發性睡眠性血紅蛋白尿症（PNH）患者
美通社
·
08/20
阿斯利康(AZN.US)瑞利珠單抗第3項適應症在中國獲批上市
智通财经
·
08/20
美股生物醫藥概念持續衝高，Moderna升逾130%，默沙東升逾11%
老虎资讯综合
·
08/19
阿斯利康(AZN.US)單抗新藥兩項適應症在中國上市
智通财经
·
08/18
第3次更新-阿斯利康因暫停volrustomig肺癌臨床試驗再遭挫折
路透中文
·
08/17
阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功
智通财经
·
08/17
阿斯利康終止一項肺癌三期臨床試驗，稱療效難達主要終點
智通财经
·
08/17
阿斯利康（AZN）再遇重大臨床研發挫折 宣佈停止肺癌治療藥物Volrustomig三期試驗
金吾财讯
·
08/17
阿斯利康（AZN）與日本第一三共聯合宣佈重磅抗體偶聯藥物Enhertu®三期臨床取得重大突破
金吾财讯
·
08/17
泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇
美通社
·
08/17
阿斯利康(AZN.US)宣佈終止其實驗性藥物volrustomig的臨床試驗，此前數據顯示，該藥物似乎無法在肺癌治療方面
智通财经
·
08/17
阿斯利康宣佈泰適卓在華上市
第一财经
·
08/17
阿斯利康宣佈泰適卓正式在華上市
智通财经
·
08/17
據美國財經媒體Semafor：英國首相顧問曾就阿斯利康與百時美施貴寶的合併事宜致電阿斯利康。
智通财经
·
08/13
市場消息：英國首相顧問就布里斯托爾併購案聯繫阿斯利康。
智通财经
·
08/13
第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市
智通财经
·
08/13
康方生物雙抗藥物獲批第三項適應證 此前擊敗百濟神州；阿斯利康加入口服減重藥「混戰」：4500人Ⅲ期臨床試驗只對標安慰劑｜掘金創新藥
每日经济新闻
·
08/13
石藥創新(300765.SZ)：巨石生物已收到阿斯利康支付的3000萬美元首付款
智通财经
·
08/12
石藥創新：控股子公司收到阿斯利康3000萬美元首付款
智通财经
·
08/12
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/AZNH/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1787688000000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"停牌","change":0,"latestTime":"08-25 19:38:10 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":44.36,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660286748","title":"阿斯利康長效C5補體抑制劑偉立瑞獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286748","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660286748?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"南方财经8月20日电，记者获悉，阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞?（英文商品名：Ultomiris?，通用名：瑞利珠单抗注射液），已获得中国国家药品监督管理局（NMPA）批准，用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症（PNH）患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年，77%的PNH患者在20-40岁发病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847950261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847950261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","BK4585","AZN","LU2237443895.HKD","LU0109394709.USD","LU2237443978.SGD","BK4568","LU2417539215.USD","LU2468319806.SGD","LU0708994859.HKD","LU2456880835.USD","LU1267930573.SGD","AZNH","IE00B3T34201.USD","LU0889565916.HKD","IPOS","LU0432979614.USD","LU0029864427.USD","BK4588","LU2237443382.USD","LU2237443465.HKD","LU2237443622.USD","LU2236285917.USD","LU0058720904.USD","LU2089984988.USD","LU0289739699.SGD","LU0128525929.USD","LU0320765992.SGD","LU2237443549.SGD","LU1829250122.USD","LU0310800379.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284301","title":"偉立瑞®在華獲批用於治療成人和1月齡及以上兒童陣發性睡眠性血紅蛋白尿症（PNH）患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284301","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660284301?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"此次瑞利珠单抗获批，为成人及儿童PNH患者带来了兼具长效性、稳定性和便利性的治疗选择，可实现快速、完全且持续的终末补体抑制。目前，瑞利珠单抗在中国、美国、欧盟、日本等国家和地区获批用于治疗特定的阵发性睡眠性血红蛋白尿症的成人及儿童患者，并在全球多个国家和地区获批多项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0128525929.USD","LU2237443549.SGD","LU2237443895.HKD","LU2468319806.SGD","LU0320765992.SGD","LU2236285917.USD","BK4007","AZNH","LU0432979614.USD","LU1829250122.USD","LU0029864427.USD","LU0708994859.HKD","LU2456880835.USD","LU0289739699.SGD","LU2417539215.USD","LU0109394709.USD","LU0889565916.HKD","LU0310800379.SGD","BK4585","LU2089984988.USD","LU2462157665.USD","LU2237443465.HKD","LU2237443622.USD","IE00B3T34201.USD","LU1267930573.SGD","LU2237443382.USD","AZN","BK4588","LU0058720904.USD","BK4568","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407362","title":"阿斯利康(AZN.US)瑞利珠單抗第3項適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660407362?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 16:50","pubTimestamp":1787215836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月20日，国家药品监督管理局官网显示，阿斯利康“瑞利珠单抗”国内再获批一项新适应症，用于治疗阵发性睡眠性血红蛋白尿症。瑞利珠单抗于2025年4月首次获批进入中国，用于治疗抗AChR抗体阳性的成人全身型重症肌无力，后又拓展适应症至NMOSD。瑞利珠单抗此次新适应症获批，成为国内第7款、进口第4款PNH治疗药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU0708994859.HKD","LU0058720904.USD","LU2462157665.USD","LU2237443978.SGD","LU0889565916.HKD","LU1267930573.SGD","LU2417539215.USD","LU0289739699.SGD","LU2237443465.HKD","LU2237443549.SGD","IPOS","LU2237443382.USD","AZNH","BK4007","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD","AZN","BK4585","LU0029864427.USD","LU0320765992.SGD","BK4568","LU2089984988.USD","LU0432979614.USD","LU0310800379.SGD","LU2456880835.USD","LU2237443895.HKD","LU2468319806.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156346136","title":"美股生物醫藥概念持續衝高，Moderna升逾130%，默沙東升逾11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156346136","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156346136?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 22:06","pubTimestamp":1787148392,"startTime":"0","endTime":"0","summary":"8月19日，美股生物医药概念持续冲高，$Moderna(MRNA)$涨幅扩大至130%，$默沙东(MRK)$涨超11%，$礼来(LLY)$涨超5%，$辉瑞(PFE)$、$诺和诺德(NVO)$、$阿斯利康(AZN)$等涨约3%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","LU2462157665.USD","LU0353189680.USD","IE0009355771.USD","LU2468319806.SGD","LU1037948897.HKD","LU0170899867.USD","LU1162221912.USD","LU2168563687.JPY","LU0823416689.USD","SGXZ99366536.SGD","IE00B775H168.HKD","LU2028103732.USD","LU0683600562.USD","LU2023250504.SGD","IE00BK4W5L77.USD","LU2213496289.HKD","IE00B1XK9C88.USD","LU1868836757.USD","LU2023250843.SGD","LU0306806265.USD","LU2063271972.USD","LU2746668461.USD","HRTS","LU2491050071.SGD","IE00BWXC8680.SGD","LU0158827948.USD","LU1066053197.SGD","SG9999014542.SGD","LU2602419157.SGD","TMED","LU1548497426.USD","LU0289739699.SGD","SG9999011175.SGD","LU2237443549.SGD","SG9999014914.USD","LU0882574139.USD","LU1061106388.HKD","LGHT","LU1929549753.HKD","SG9999015952.SGD","LU0203202063.USD","IE0002141913.USD","BK4550","BK4533","XBI","LU2237443622.USD","IE00BKPKM429.USD","LU2106854487.HKD","LU0128525929.USD","SG9999001176.USD","TRUH","LU0820562030.AUD","WDNA","LU0133085943.USD","LU2237438978.USD","LU0198837287.USD","LU1127390331.HKD","LU2750360997.AUD","LU1093756325.SGD","LU1934455277.USD","PAWZ","LU0471298694.HKD","LU1291159041.SGD","LU2361044949.HKD","LU0354030511.USD","LU0154236417.USD","SG9999014567.USD","LU0820561818.USD","LU0964807845.USD","LU0097036916.USD","GNOM","LU2237443465.HKD","LU0130102774.USD","LU0109391861.USD","LU0787776722.HKD","BK4559","LU1989772923.USD","BMED","LU2361045086.USD","IE00BJT1NW94.SGD","LU1551013425.SGD","LU0029864427.USD","IE00BJJMRY28.SGD","LU1232071149.USD","BK4581","IE0004445239.USD","BK4592","LU1883839398.USD","IE00BJJMRZ35.SGD","IE00BLSP4239.USD","LU2089283258.USD","LU0098860793.USD","SG9999001176.SGD","CURE","MRNY","LU1035775433.USD","LU0158827781.USD","XLV","IHE","LU0094547139.USD","LU1989772840.SGD","BK4551","GB00BDT5M118.USD","LU1037948541.HKD","LU1035773651.USD","LU2324357040.USD","LU2023251221.USD","IE00B3T34201.USD","LU1267930730.SGD","LU1623119135.USD","IE00BBT3K403.USD","LU0310800379.SGD","LU2756315318.SGD","LU0985481810.HKD","LU1280957306.USD","LU0208291251.USD","LU0965509101.SGD","LU2756315664.SGD","IE00BFSS7M15.SGD","LU0320765059.SGD","IE00BSNM7G36.USD","LU0985320562.USD","IE00BLSP4452.SGD","SG9999003800.SGD","SG9999001440.SGD","BK4588","BK4532","BK4568","LU2087625088.SGD","LU1923622614.USD","LU0306807586.USD","LU0965509010.AUD","CANC","LU1983299246.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","MEDX","IE00B4JS1V06.HKD","SG9999013999.USD","BK4534","LU0385154629.USD","LU2211815571.USD","LU1066051811.HKD","LU0225771236.USD","LU0203201768.USD","LU2552382132.HKD","MRNX","LU0965509283.SGD","IXJ","LU0648001328.SGD","LU1093756168.USD","LU0321505868.SGD","LU0265550946.USD","LU1571399168.USD","LU1934455863.HKD","ILDR","LU0889565916.HKD","LU0466842654.USD","LU1267930573.SGD","BK4007","LU1814569148.SGD","IE00BK4W5M84.HKD","SGXZ81514606.USD","161726","LU2456880835.USD","LU1934455194.USD","JDOC","IE0004445015.USD","LU0124676726.USD","LU0823434740.USD","LU2236285917.USD","IE00BJLML261.HKD","LU0316494557.USD","LU1712237335.SGD","LU0096364046.USD","LU1988902786.USD","LU0238689110.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU2125154935.USD","SG9999018865.SGD","LU1941712348.USD","PPH","LU2237443895.HKD","OZEM","IE00B4R5TH58.HKD","LU0689626769.HKD","LU1979441026.SGD","LU2271345857.HKD","LU1894683348.USD","SG9999014575.USD","LU0070302665.USD","LU2357627491.SGD","SG9999002232.USD","LU0456855351.SGD","LU2471134952.CNY","LU2357305700.SGD","LU2265009873.SGD","FHLC","BK7095","GDOC","LU2264538146.SGD","LU2168564495.EUR","LU1894683264.USD","LU1069347547.HKD","PJP","LU1868836914.USD","LU2433249047.HKD","LU2168564222.USD","LU0320765489.SGD","LU0006306889.USD","LU1941712264.USD","IE00BZ1G4Q59.USD","LU1829250122.USD","LU0672654240.SGD","LU1917777945.USD","LU0965508806.USD","LU2491050154.USD","LU1145028129.USD","LU1720051108.HKD","LU2461242641.AUD","LU0786609619.USD","LU0256863902.USD","SG9999014898.SGD","BK4139","LU0203347892.USD","IE0005OL40V9.USD","IE00B7KXQ091.USD","LU0061475181.USD","LU0861579265.USD","LU0345770993.USD","LU2237443978.SGD","SG9999017495.SGD","BK4516","IE000M9KFDE8.USD","LU1057294990.SGD","VHT","LU2089284900.SGD","LU2471134879.HKD","BK4548","LU1323610961.USD","LU0320765646.SGD","SG9999015358.SGD","LU2361044865.SGD","LU1066051225.USD","LU0640476718.USD","LU0079474960.USD","THNR","LU1720051017.SGD","LU1699723380.USD","IE00BN29S564.USD","LU1868837300.USD","LU0130517989.USD","LU1804176565.USD","LU0321505439.SGD","SGXZ31699556.SGD","IE0002270589.USD","RXL","LU2168564149.EUR","LU2750360641.GBP","LU2896262040.SGD","LU0417517546.SGD","LU2125909247.SGD","BK4501","IE00BFSS8Q28.SGD","LU1868836591.USD","IYH","LU0942090050.USD","LU1116320737.USD","LU1116320901.HKD","LU0234572021.USD","LU0174119429.USD","LU0882574055.USD","LU2111349929.HKD","LU2360032135.SGD","MEDI","LU2746668974.SGD","MRK","LU2552382215.SGD","IE00B2B36J28.USD","BK4599","AZNH","LU2471134523.USD","LU0868494708.USD","LU0211331839.USD","LU0345770308.USD","SG9999014880.SGD","FTXH","MHIP","LU2596442595.SGD","LU0210536198.USD","IE00BN8TJ469.HKD","LU1430594728.SGD","LU2491049909.HKD","LU1066051498.USD","LU0353189763.USD","LU2108987350.USD","LU1366192091.USD","AGNG","SG9999014906.USD","LU2237443382.USD","LU0477156953.USD","LU0943347566.SGD","LU0122379950.USD","LU0820561909.HKD","LU2125909593.SGD","IE00B1BXHZ80.USD","LU0823434583.USD","LU1064131342.USD","LU1629891620.HKD","BK7104","SG9999015945.SGD","LU2112291526.USD","LU2023250330.USD","LU0708995401.HKD","IE00BKVL7J92.USD","LU1023059063.AUD","LU1551013342.USD","LU0106261372.USD","LU1201861249.SGD","LU0203345920.USD","IE00BJJMRX11.SGD","BGIA","SGXZ57979304.SGD","LU0225284248.USD","LU0471298777.SGD","LU2462591350.SGD","LU0320765992.SGD","LU0109394709.USD","SG9999014559.SGD","LU0708994859.HKD","LU0859254822.USD","SG9999015978.USD","IE00BKDWB100.SGD","LU0058720904.USD","LU0868494617.USD","SG9999015341.SGD","LU1974910355.USD","SG9999018857.SGD","LU2552382058.USD","SGXZ51526630.SGD","LU0256863811.USD","LU0980610538.SGD","LU0323591593.USD","LU1585245621.USD","LU0114720955.EUR","LU2417539215.USD","BK4585","LU2471134796.USD","IDNA","LU0432979614.USD","LU0265550359.USD","IE00B19Z3581.USD","SG9999015986.USD","LU0354030438.USD","MRNA","LU2360106947.USD","LU1069344957.HKD","LU2089984988.USD","LU1989771016.USD","LU1868837136.USD","IE0001KFT4U8.USD","LU0689472784.USD","LU1691799644.USD","LU2168564065.EUR","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450919","title":"阿斯利康(AZN.US)單抗新藥兩項適應症在中國上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660450919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 15:41","pubTimestamp":1787038869,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康宣布，特泽利尤单抗注射液在中国正式上市。2026年3月，特泽利尤单抗基于DIRECTION及WAYPOINT两项3期临床研究的阳性结果，在中国获批两项适应症：用于成人和12岁及以上青少年重度哮喘的维持治疗；本品与鼻用糖皮质激素联合使用，治疗系统性糖皮质激素和/或手术治疗无法充分控制疾病的慢性鼻窦炎伴鼻息肉成人患者。特泽利尤单抗是由阿斯利康与安进合作开发的人源单克隆抗体，可抑制TSLP的活性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0128525929.USD","LU2462157665.USD","LU0310800379.SGD","LU0289739699.SGD","BK4585","LU0889565916.HKD","LU0058720904.USD","LU0432979614.USD","LU1267930573.SGD","LU2456880835.USD","LU1829250122.USD","LU2468319806.SGD","LU0708994859.HKD","LU0109394709.USD","LU2417539215.USD","LU2237443978.SGD","BK4007","AZN","LU2236285917.USD","LU0029864427.USD","LU2237443895.HKD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU2237443622.USD","AZNH","BK4588","LU2089984988.USD","BK4568","LU0320765992.SGD","IPOS","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660498480","title":"第3次更新-阿斯利康因暫停volrustomig肺癌臨床試驗再遭挫折","url":"https://stock-news.laohu8.com/highlight/detail?id=2660498480","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660498480?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971447,"startTime":"0","endTime":"0","summary":"阿斯利康此前曾预测，volrustomig的峰值销售额将超过50亿美元。该公司表示，volrustomig与化疗联合使用时的安全性特征与各药物已知的安全性特征一致，未发现新的安全性信号。Volrustomig是一种双重检查点抑制剂双特异性抗体，旨在解除PD-1和CTLA-4这两条关键免疫通路的抑制，从而帮助免疫系统攻击肿瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU0708994859.HKD","LU0058720904.USD","LU2462157665.USD","LU2237443978.SGD","LU0889565916.HKD","LU1267930573.SGD","LU2417539215.USD","LU0289739699.SGD","LU2237443465.HKD","LU2237443549.SGD","LU2237443382.USD","AZNH","BK4007","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD","AZN","BK4585","LU0029864427.USD","LU0320765992.SGD","BK4568","LU2089984988.USD","LU0432979614.USD","LU0310800379.SGD","LU2456880835.USD","LU2237443895.HKD","LU2468319806.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一線治療肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660248062?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0058720904.USD","LU1829250122.USD","LU2237443978.SGD","LU0128525929.USD","LU0109394709.USD","III","LU2237443549.SGD","ADC","LU0889565916.HKD","LU2236285917.USD","NETL","BK4134","IE00B3T34201.USD","LU2237443622.USD","LU0432979614.USD","LU0708994859.HKD","BK4231","LU0029864427.USD","BK4080","BK4007","AZNH","LU0289739699.SGD","LU0320765992.SGD","AZN","LU2237443465.HKD","LU2468319806.SGD","LU2417539215.USD","BK4585","LU2456880835.USD","LU2089984988.USD","LU0310800379.SGD","LU1267930573.SGD","BK4568","LU2237443382.USD","LU2237443895.HKD","BK4588","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660147484","title":"阿斯利康終止一項肺癌三期臨床試驗，稱療效難達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660147484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660147484?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:11","pubTimestamp":1786965064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LU2237443465.HKD","LU2237443895.HKD","LU0320765992.SGD","IE00B3T34201.USD","MDTX","LU0310800379.SGD","IBBJ","LU2237443549.SGD","BK4007","BMED","LU2456880835.USD","LU0889565916.HKD","LU0128525929.USD","LU2468319806.SGD","BK4568","AZN","LU2237443622.USD","LU0432979614.USD","LU2237443382.USD","LU0029864427.USD","LU2236285917.USD","BK4588","BK4585","LU2237443978.SGD","LU1267930573.SGD","LU2089984988.USD","LU2462157665.USD","LU0708994859.HKD","LU0289739699.SGD","AZNH","LU0058720904.USD","LU2417539215.USD","LU1829250122.USD","LU0109394709.USD","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660485253","title":"阿斯利康（AZN）再遇重大臨床研發挫折 宣佈停止肺癌治療藥物Volrustomig三期試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2660485253","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660485253?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:52","pubTimestamp":1786956744,"startTime":"0","endTime":"0","summary":"研究结果显示，与现有的标准治疗方案相比，Volrustomig联合化疗未能显著提升晚期肺癌患者的生存率。值得注意的是，这也是阿斯利康在过去一个月内遭遇的第二次重大临床研发挫折。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443895.HKD","BK4007","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660362485","title":"阿斯利康（AZN）與日本第一三共聯合宣佈重磅抗體偶聯藥物Enhertu®三期臨床取得重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2660362485","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660362485?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:41","pubTimestamp":1786956109,"startTime":"0","endTime":"0","summary":"金吾财讯 | 跨国制药巨头阿斯利康 与日本第一三共联合宣布，其合作开发的重磅抗体偶联药物Enhertu在代号为“DESTINY-Lung04”的全球三期临床试验中取得积极成果。这是全球首个且唯一在HER2突变型非小细胞肺癌一线治疗中战胜标准疗法的HER2靶向药物。据悉，HER2突变型非小细胞肺癌约占非小细胞肺癌患者的2%至4%，常见于较年轻且无吸烟史的女性患者，侵袭性强且易发生脑转移。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU1267930573.SGD","LU2456880835.USD","LU0708994859.HKD","IE00B3T34201.USD","LU2237443549.SGD","BK4588","LU2237443895.HKD","LU2237443622.USD","AZN","LU0058720904.USD","LU2237443978.SGD","LU0310800379.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU2237443465.HKD","LU2468319806.SGD","LU1829250122.USD","BK4007","LU0029864427.USD","LU2417539215.USD","LU0889565916.HKD","LU2236285917.USD","LU0109394709.USD","LU0320765992.SGD","LU0432979614.USD","LU0128525929.USD","LU2089984988.USD","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660334481","title":"泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2660334481","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660334481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:21","pubTimestamp":1786954860,"startTime":"0","endTime":"0","summary":"特泽利尤单抗的上市，为慢性鼻窦炎伴鼻息肉患者带来了新的治疗选择，有望帮助他们实现长期疾病控制，改善生活质量。携双适应症在华上市，特泽利尤单抗有望充分释放上游炎症通路靶点的临床价值，进一步完善我们在哮喘领域从轻中度到重度的全病程疾病管理布局，加速哮喘治疗迈向'临床治愈'愿景，同时满足广大慢性鼻窦炎伴鼻息肉患者的未尽之需。其中，高达10%的哮喘患者为重度哮喘22,23。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0708994859.HKD","LU2456880835.USD","BK4007","AZN","LU2237443382.USD","LU0432979614.USD","IE00B3T34201.USD","LU1267930573.SGD","LU0109394709.USD","LU0889565916.HKD","BK4588","LU2236285917.USD","BK4568","LU2237443622.USD","LU0029864427.USD","LU2237443549.SGD","LU2089984988.USD","LU2237443465.HKD","LU1829250122.USD","LU2417539215.USD","BK4585","ENTL","LU2237443978.SGD","LU2237443895.HKD","LU0320765992.SGD","LU0058720904.USD","AZNH","LU0289739699.SGD","LU2462157665.USD","LU0310800379.SGD","LU0128525929.USD","IPOS","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660072601","title":"阿斯利康(AZN.US)宣佈終止其實驗性藥物volrustomig的臨床試驗，此前數據顯示，該藥物似乎無法在肺癌治療方面","url":"https://stock-news.laohu8.com/highlight/detail?id=2660072601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660072601?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:48","pubTimestamp":1786949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0889565916.HKD","PSYK","AZN","LU2462157665.USD","LU0310800379.SGD","LU0432979614.USD","BK4585","LU2237443622.USD","BMED","LU2089984988.USD","BK4568","MDTX","LU2456880835.USD","BK4007","LU2237443978.SGD","LU2237443895.HKD","IBBQ","LU0289739699.SGD","LU2417539215.USD","LU2237443549.SGD","IE00B3T34201.USD","LU0320765992.SGD","LU0708994859.HKD","LU0128525929.USD","LU2468319806.SGD","AZNH","LU2237443382.USD","LU1829250122.USD","LU2236285917.USD","IBBJ","BK4588","LU0029864427.USD","LU1267930573.SGD","LU0058720904.USD","LU2237443465.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660074241","title":"阿斯利康宣佈泰適卓在華上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660074241","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660074241?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:24","pubTimestamp":1786947859,"startTime":"0","endTime":"0","summary":"阿斯利康宣布泰适卓在华上市","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843083635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843083635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0708994859.HKD","LU2237443465.HKD","LU0432979614.USD","IE00B3T34201.USD","LU2237443978.SGD","LU0889565916.HKD","LU0310800379.SGD","LU0128525929.USD","LU0109394709.USD","LU0289739699.SGD","BK4007","LU1267930573.SGD","LU2236285917.USD","BK4568","LU2089984988.USD","LU2237443622.USD","LU0058720904.USD","AZNH","LU2417539215.USD","LU2237443549.SGD","LU0320765992.SGD","LU2237443382.USD","LU2468319806.SGD","BK4585","LU2456880835.USD","LU2237443895.HKD","IPOS","LU2462157665.USD","LU1829250122.USD","AZN","BK4588","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660107356","title":"阿斯利康宣佈泰適卓正式在華上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660107356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660107356?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 14:19","pubTimestamp":1786947557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","AZNH","LU2456880835.USD","LU1267930573.SGD","LU2462157665.USD","LU0310800379.SGD","LU0432979614.USD","LU2236285917.USD","LU0128525929.USD","LU2089984988.USD","LU2237443382.USD","LU2237443895.HKD","LU0109394709.USD","LU0058720904.USD","LU2237443465.HKD","LU2237443549.SGD","IPOS","LU0889565916.HKD","LU2468319806.SGD","LU0708994859.HKD","LU0320765992.SGD","BK4568","LU0289739699.SGD","BK4585","LU0029864427.USD","LU2237443622.USD","LU2417539215.USD","IE00B3T34201.USD","LU1829250122.USD","BK4007","LU2237443978.SGD","AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416555","title":"據美國財經媒體Semafor：英國首相顧問曾就阿斯利康與百時美施貴寶的合併事宜致電阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416555","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416555?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 23:14","pubTimestamp":1786634047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2468319806.SGD","LU1261432733.SGD","IE00B2B36J28.USD","BK4532","AZNH","IE00B3T34201.USD","LU0029864427.USD","LU0096364046.USD","LU1868836757.USD","LU0128525929.USD","LU2456880835.USD","AZN","LU1670711123.USD","LU0237698245.USD","LU2242646821.SGD","BK4559","LU2237443978.SGD","IE00BJJMRZ35.SGD","LU2360032135.SGD","LU1430594728.SGD","LU0882574055.USD","LU0432979614.USD","BMY","LU1989771016.USD","LU1829250122.USD","LU2125154935.USD","LU1093756168.USD","LU2237443465.HKD","FTXH","LU2089984988.USD","BK4588","LU2125154778.USD","LU2242652126.USD","LU0267386448.USD","LU0456855351.SGD","BK4581","LU1032466523.USD","LU1267930573.SGD","LU0289739699.SGD","IE00BFXG1179.USD","LU0109394709.USD","LU1883839398.USD","LU2236285917.USD","LU1868836591.USD","LU0985481810.HKD","IE00BFTCPJ56.SGD","LU2596442595.SGD","IHE","LU0708994859.HKD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165315","title":"市場消息：英國首相顧問就布里斯托爾併購案聯繫阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165315?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 23:13","pubTimestamp":1786633991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2468319806.SGD","BK4585","LU0029864427.USD","AZNH","IE00B3T34201.USD","LU2237443622.USD","LU0128525929.USD","LU2456880835.USD","LU0058720904.USD","AZN","LU2237443382.USD","LU2417539215.USD","LU0889565916.HKD","LU2237443978.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443465.HKD","LU2089984988.USD","LU2462157665.USD","LU2237443549.SGD","BK4588","LU1267930573.SGD","LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","LU2237443895.HKD","BK4007","BK4568","LU0708994859.HKD","LU0310800379.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659860121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU0889565916.HKD","IPOS","NETL","LU2417539215.USD","LU0109394709.USD","LU2456880835.USD","LU2462157665.USD","LU2237443465.HKD","LU1267930573.SGD","AZN","LU0310800379.SGD","LU2236285917.USD","LU2237443622.USD","LU0320765992.SGD","LU0128525929.USD","BK4585","BK4588","BK4080","LU0289739699.SGD","LU0708994859.HKD","LU2468319806.SGD","BK4568","LU1829250122.USD","LU2237443549.SGD","LU2237443978.SGD","LU2237443382.USD","LU2237443895.HKD","ADC","LU0058720904.USD","IE00B3T34201.USD","LU0432979614.USD","BK4231","LU0029864427.USD","LU2089984988.USD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659901270","title":"康方生物雙抗藥物獲批第三項適應證 此前擊敗百濟神州；阿斯利康加入口服減重藥「混戰」：4500人Ⅲ期臨床試驗只對標安慰劑｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2659901270","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659901270?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 01:22","pubTimestamp":1786555325,"startTime":"0","endTime":"0","summary":"资本眼一周行情上周（8月3日至8月7日），医药生物指数上涨4.63%，跑赢上证指数（周内上涨2.81%）1.82个百分点。创新药（BK1106）周内上涨8.66%；恒生医疗保健业指数（HSCICH）周内上涨8.09%；港股创新药ETF广发（513120）周内上涨8.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839529518.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839529518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AZNH","PSYK","LU0348784397.USD","IE00B5MMRT66.SGD","KURE","MEDX","BK0239","IBBQ","LU0708994859.HKD","LU2476274720.SGD","09926","BK4588","IBBJ","LU2237443622.USD","06978","LU1251922891.USD","AZN","LNGR","LU0307460666.USD","LU2237443895.HKD","MDTX","06160","LU1969619763.USD","LU0058720904.USD","LU0348766576.USD","688235","LU0588546209.SGD","LU0417516738.SGD","LU0310800379.SGD","LU0348783233.USD","LU0289739699.SGD","LU1770034418.SGD","BK1583","BK1161","LU2237443382.USD","LU2237443465.HKD","BK4007","ONC","159992","LU0109394709.USD","LU0320765992.SGD","LU0634319403.HKD","IE00BPRC5H50.USD","LU0432979614.USD","LU0128525929.USD","LU2488822045.USD","LU2089984988.USD","BMED","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658769979","title":"石藥創新(300765.SZ)：巨石生物已收到阿斯利康支付的3000萬美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658769979","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658769979?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:52","pubTimestamp":1786531939,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新(300765.SZ)发布公告，2026年7月1日，公司控股子公司巨石生物与阿斯利康签署《合作、选择权及授权协议》，将与阿斯利康在新型小干扰核酸候选药物领域开展战略合作，开发新型肝外递送小干扰分子核酸候选药物。根据协议约定，巨石生物已于2026年8月12日收到阿斯利康支付的3000万美元首付款(实际到账金额须扣除银行手续费)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479073.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU0058720904.USD","BK4568","LU0432979614.USD","LU2236285917.USD","LU2462157665.USD","LU2237443895.HKD","LU0128525929.USD","BK4588","300765","LU0310800379.SGD","BK0226","BK4007","LU0029864427.USD","LU2237443978.SGD","AZNH","LU1829250122.USD","LU1267930573.SGD","LU2417539215.USD","LU0289739699.SGD","LU2237443622.USD","LU2456880835.USD","LU0889565916.HKD","AZN","LU0320765992.SGD","LU2468319806.SGD","LU2237443549.SGD","IE00B3T34201.USD","LU0109394709.USD","LU0708994859.HKD","LU2237443465.HKD","LU2089984988.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658811976","title":"石藥創新：控股子公司收到阿斯利康3000萬美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658811976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658811976?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 18:06","pubTimestamp":1786529180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443465.HKD","LU2236285917.USD","LU0320765992.SGD","LU2456880835.USD","LU1267930573.SGD","LU2417539215.USD","LU2237443895.HKD","LU0058720904.USD","LU2237443549.SGD","LU2237443382.USD","IE00B3T34201.USD","LU1829250122.USD","LU2468319806.SGD","BK4585","AZN","LU2462157665.USD","BK4588","LU0289739699.SGD","LU0889565916.HKD","LU0128525929.USD","LU0432979614.USD","LU0029864427.USD","BK4007","BK4568","LU2089984988.USD","LU0708994859.HKD","LU2237443978.SGD","LU2237443622.USD","AZNH","LU0109394709.USD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":148,"code":"91000000","status":"200"}]}}